Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity, however, four mutations accounts for the majority of the poor metabolizers. Genomic DNA was etracted from a total of 109 EDTA-supplemented blood samples of patients with dilated cardiomyopathy.Sławomir Smolik...
Keywords: cyp2d6,poor metabolizer,metoclopramide,acute dystonia,metoclopramide-induced acute dystonic reactions,pharmacogenetics,pharmacogenomics Data availability: ScienceOpen disciplines: Pharmacology & Pharmaceutical medicine Keywords: cyp2d6, poor metabolizer, metoclopramide, acute dystonia, metoclopramide-induced ...
Further, the study aimed to investigate whether the previously observed frequency of CYP2D6 poor metabolizers (PMs) in the Faroese, which was shown to ... J Halling,P Weihe,K Brosen - 《Therapeutic Drug Monitoring》 被引量: 130发表: 2008年 Multiple mutations of the human cytochrome P450 ...
CYP2D6 poor metabolizers have no CYP2D6 activity (7% of whites and 1%-2% of other races). ... LJ De,MT Susce,RM Pan,... - 《Journal of Clinical Psychiatry》 被引量: 502发表: 2005年 The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode ...
Variants in the CYP2D6 gene can cause patients to be either intermediate or poor metabolizers, thereby rendering tamoxifen treatment less effective. Testing for CYP2D6 gene variants is available in Clinical Laboratory Improvement Amendments–certified clinical labora- tories; however, the biological ...
Two poor metabolizer individuals of debrisoquine were identified among 215 healthy Japanese by a phenotyping test. Analysis of the CYP2D6 gene from one of two poor metabolizers, who was not homozygous for the previously described CYP2D6 variant alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP...
The genotyping probe for rs3892097 used to call the CYP2D6 *4 allele failed, resulting in an inconclusive CYP2D6 diplotype of either (*4/*40)2N or (*10/*40)2N that would translate to a poor metabolizer (PM) or intermediate metabolizer (IM) phenotype, respectively, using the CYP2D6 ...
The frequencies of phenotypes in affected patients were 8.4 % intermediate metabolizers (IMs), 8.4 % poor metabolizers (PMs) and 3.1 % ultrafast metabolizers (UMs), whereas 52.4 % were extensive metabolizers (EMs) and 27.6 % heterozygous EMs. 展开 ...
extensive,intermediateandpoor metabolizersofeitherCYP2D6orCYP2C19给予不同的剂量.对于三环类抗抑郁药物,或者是CYP2D6的底物或者CYP2C19的底物的不良代谢者，他的使用量降低了，而选择性5羟色胺再吸收抑制剂在各个代谢类型人群中量的差异是很小的。•Conclusion:我们基于基因型和蛋白型提供了初步的平均量建议.这时应用...
关键词: Poor Metabolizer Hand Grip Strength Frail Patient CYP2D6 Genotype CYP2D6 Activity DOI: 10.1007/s40266-015-0319-0 年份: 2015 收藏 引用 批量引用 报错 分享 全部来源 免费下载 求助全文 全文购买 Springer 国家科技图书文献中心 (权威机构) 掌桥科研 dx.doi.org Europe PMC 查看更多 相似文献 ...